Comparison of structural and functional outcome of aflibercept versus ranibizumab in patients with myopic choroidal neovascularization.

CONCLUSION: Both aflibercept and ranibizumab provided a significant improvement in visual acuity and retinal thickness in patients with myopic choroidal neovascularization. Comparable functional and architectural results were achieved by both treatment modalities. PMID: 31690105 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31690105?dopt=Abstract

Source: European Journal of Ophthalmology - November 4, 2019 Category: Opthalmology Authors: Howaidy A, Eldaly ZH Tags: Eur J Ophthalmol Source Type: research